| DESCRIPTION | - ABRAHAM, R.T., Current Opinion in Immunology., (19960000), vol. 8, no. 3, pages 412 - 8 | - |
| DESCRIPTION | - ADAMS JKAUFFMAN M, Cancer Invest, (20040000), vol. 22, no. 2, pages 304 - 11 | - |
| DESCRIPTION | - ASHBY, M.N., Current Opinion in Lipidology., (19980000), vol. 9, no. 2, pages 99 - 102 | - |
| DESCRIPTION | - BALASUBRAMANIAN et al., Cancer Letters, (20090000), vol. 280, pages 211 - 221 | - |
| DESCRIPTION | - BALL et al., Progress in Cell Cycle Res., (19970000), vol. 3, page 125 | - |
| DESCRIPTION | - BERTRAND, European Journal of Medicinal Chemistry, (20100000), vol. 45, pages 2095 - 2116 | - |
| DESCRIPTION | - BioChim. Biophys. Acta, (19990819), vol. 1423, no. 3, pages 19 - 30 | - |
| DESCRIPTION | - BOLEN, J.B.BRUGGE, J.S., Annual review of Immunology., (19970000), vol. 15, pages 371 - 404 | - |
| DESCRIPTION | - BOUMA et al., J. Antimicrob. Chemother., (19980000), vol. 42, no. 6, pages 817 - 20 | - |
| DESCRIPTION | - BREKKEN, R.A. et al., "Selective Inhibition of VEGFR2 Activity by a monoclonal Anti-VEGF antibody blocks tumor growth in mice", Cancer Res., (20000000), vol. 60, pages 5117 - 5124, XP002340113 | - |
| DESCRIPTION | - BRODT, PSAMANI, A.NAVAB, R., Biochemical Pharmacology, (20000000), vol. 60, pages 1101 - 1107 | - |
| DESCRIPTION | - CANMAN, C.E.LIM, D.S., Oncogene, (19980000), vol. 17, no. 25, pages 3301 - 3308 | - |
| DESCRIPTION | - CHEN YHU DELING DJROBBINS JKIPPS TJ, Cancer Res., (19980000), vol. 58, pages 1965 - 1971 | - |
| DESCRIPTION | - D. A. TENNANT, Nature Reviews, (20100000), vol. 267 | - |
| DESCRIPTION | - Drugs of the Future, (20070000), vol. 32, no. 4, pages 315 - 322 | - |
| DESCRIPTION | - FELING, Angew. Chem. Int. Ed. Engl., (20030000), vol. 42, no. 3, pages 355 - 7 | - |
| DESCRIPTION | - GOTTLICHER et al., EMBO J., (20010000), vol. 20, no. 24, pages 6969 - 6978 | - |
| DESCRIPTION | - HOLMES et al., J. Nat. Cancer Inst., (19910000), vol. 83, page 1797 | - |
| DESCRIPTION | - JACKSON, S.P., International Journal of Biochemistry and Cell Biology., (19970000), vol. 29, no. 7, pages 935 - 8 | - |
| DESCRIPTION | - KEARNS, C.M., Seminars in Oncology, (19950000), vol. 3, no. 6, pages 16 - 23 | - |
| DESCRIPTION | - KITADA S, Antisense Res. Dev., (19940000), vol. 4, pages 71 - 79 | - |
| DESCRIPTION | - KUMAR, J. Biol, Chem, (19810000), vol. 256, pages 10435 - 10441 | - |
| DESCRIPTION | - LACKEY, K. et al., Bioorganic and Medicinal Chemistry Letters, (20000000), no. 10, pages 223 - 226 | - |
| DESCRIPTION | - MARKMAN et al., Yale Journal of Biology and Medicine, (19910000), vol. 64, page 583 | - |
| DESCRIPTION | - MARKS et al., Nature Biotechnology, (20070000), vol. 25, pages 84 - 90 | - |
| DESCRIPTION | - MARTINEZ-LACACI, L. et al., Int. J. Cancer, (20000000), vol. 88, no. 1, pages 44 - 52 | - |
| DESCRIPTION | - MASSAGUE, J.WEIS-GARCIA, F, Cancer Surveys., (19960000), vol. 27, pages 41 - 64 | - |
| DESCRIPTION | - MCGUIRE et al., Ann. Intem, Med., (19890000), vol. 111, page 273 | - |
| DESCRIPTION | - "New trends in Natural Products Chemistry 1986", D. G. I. KINGSTON et al., Studies in Organic Chemistry, Elsever, (19860000), vol. 26, pages 219 - 235 | - |
| DESCRIPTION | - PEARCE, L.R et al., Nature Reviews Molecular Cell Biology, (20100000), vol. 11, pages 9 - 22 | - |
| DESCRIPTION | - PHILIP, P.A.HARRIS, A.L., Cancer Treatment and Research., (19950000), vol. 78, pages 3 - 27 | - |
| DESCRIPTION | - P. LEDER, Cancer Cell, (20060000), vol. 9, page 425 | - |
| DESCRIPTION | - REILLY RT et al., Cancer Res., (20000000), vol. 60, pages 3569 - 3576 | - |
| DESCRIPTION | - RICHON et al., Proc. NatAcad. Sci. U.S.A., (20000000), vol. 97, no. 18, pages 10014 - 10019 | - |
| DESCRIPTION | - ROSANIA et al., Exp. Opin. Ther. Patents, (20000000), vol. 10, no. 2, pages 215 - 230 | - |
| DESCRIPTION | - SCHAROVSKY, O.G., ROZADOS, V.R., GERVASONI, S.I. MATAR, P., Journal of Biomedical Science., (20000000), vol. 7, no. 4, pages 292 - 8 | - |
| DESCRIPTION | - SCHIFF et al., Nature, (19790000), vol. 277, pages 665 - 667 | - |
| DESCRIPTION | - SCHIFF et al., Proc. Natl, Acad, Sci. USA, (19800000), vol. 77, pages 1561 - 1565 | - |
| DESCRIPTION | - SCHREIBER ABWINKLER MEDERYNCK R., Science, (19860000), vol. 232, pages 1250 - 1253 | - |
| DESCRIPTION | - SHAWVER et al., DDT, (19970200), vol. 2, no. 2 | - |
| DESCRIPTION | - SINH, S.COREY, S.J., Journal of Hematotherapy and Stem Cell Research, (19990000), vol. 8, no. 5, pages 465 - 80 | - |
| DESCRIPTION | - SMITHGALL, T.E., Journal of Pharmacological and Toxicological Methods., (19950000), vol. 34, no. 3, pages 125 - 32 | - |
| DESCRIPTION | - STENGER, Community Oncology, (20070000), vol. 4, pages 384 - 386 | - |
| DESCRIPTION | - TYROSINE KINASE, "Signalling in Breast cancer:erbB Family Receptor Tyrosine Kniases", Breast cancer Res., (20000000), vol. 2, no. 3, pages 176 - 183 | - |
| DESCRIPTION | - VIGUSHIN et al., Anticancer Drugs, (20020100), vol. 13, no. 1, pages 1 - 13 | - |
| DESCRIPTION | - VINODHKUMAR et al., Biomedicine & Pharmacotherapy, (20080000), vol. 62, pages 85 - 93 | - |
| DESCRIPTION | - WANI et al., J. Am. Chem, Soc., (19710000), vol. 93, page 2325 | - |
| DESCRIPTION | - WATER JS et al., J. Clin. Oncol., (20000000), vol. 18, pages 1812 - 1823 | - |
| DESCRIPTION | - WILLIAMSON et al., The Journal of Allergy and Clinical Immunology, (20061200), vol. 118, no. 6, pages 1369 - 74 | - |
| DESCRIPTION | - WOO, Nature, (19940000), vol. 368, page 750 | - |
| DESCRIPTION | - YAMAMOTO, T.TAYA, S.KAIBUCHI, K., Journal of Biochemistry, (19990000), vol. 126, no. 5, pages 799 - 803 | - |
| DESCRIPTION | - YEN LET, Oncogene, (20000000), vol. 19, pages 3460 - 3469 | - |
| DESCRIPTION | - ZHONG, H. et al., Cancer res, (20000000), vol. 60, no. 6, pages 1541 - 1545 | - |
| DESCRIPTION | - GREEN, M.C. et al., "Monoclonal Antibody Therapy for Solid Tumors", Cancer Treat. Rev., (20000000), vol. 26, no. 4, doi:10.1053/ctrv.2000.0176, pages 269 - 286, XP009019784 | |
| OPPOSITION | - Alastair J. Florence, "8. The Solid State", Alastair J. Florence, Alexander T. Florence, Jürgen Siepmann, Modern Pharmaceutics, Volume 1, Basic Principles and Systems, USA, Inc. , Informa Healthcare , (20100101), pages 253 - 310, ISBN 1-4200-6564-5, XP009561944 | - |
| OPPOSITION | - Alderborn Goran, "Tablets and compaction", Pharmaceutics: The Science of Dosage Form Design, Churchill Livingstone, (20020101), pages 397 - 440, XP093109030 | - |
| OPPOSITION | - Anonymous, "ICH Topic E4 Dose Response Information to Support Drug Registration - NOTE FOR GUIDANCE ON DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION (CPMP/ICH/378/95) ", European Medicines Agency; CPMP/ICH/378/95, (19941101), European Medicines Agency; CPMP/ICH/378/95, (20240412), XP093150955 | - |
| OPPOSITION | - Anonymous, "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212", ClinicalTrials.gov; NCT01072175, (20100218), ClinicalTrials.gov; NCT01072175, URL: https://clinicaltrials.gov/study/NCT01072175?term=NCT01072175&rank=1&a=1, XP093237323 | - |
| OPPOSITION | - Anonymous, "Mekinist 2 mg film-coated tablets - Summary of Product Characteristics", Novartis Pharmaceuticals UK Ltd, (20240905), XP093237337 | - |
| OPPOSITION | - Anonymous, "MEKINIST ® (trametinib) tablets, for oral use - HIGHLIGHTS OF PRESCRIBING INFORMATION ", FDA, (20220601), FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204114s024lbl.pdf, XP093281902 | - |
| OPPOSITION | - Anonymous, "Suspension (Chemie) ", Wikipedia, (20241014), Wikipedia, URL: https://de.wikipedia.org/w/index.php?title=Suspension_(Chemie)&oldid=249411678, XP093237329 | - |
| OPPOSITION | - Batchelor, "MEK and BRAF Therapy Combo Promising for Advanced Melanoma", (20110605), URL: http://www.onclive.com/conference-coverage/asco-2011/MEK-and-BRAF-Therapy-Combo-Promising-for-Advanced-Melanoma, (20150520), XP055190338 | - |
| OPPOSITION | - Brittain Harry G, Et Al, "Effects of Polymorphism and Solid-State Solvation on Solubility and Dissolution Rate", Polymorphism in Pharmaceutical Solids, Informa , (20090101), pages 436 - 480, XP055796504 | - |
| OPPOSITION | - "Chapter 12; Chapter 31", Michael E. Aulton, Aulton’s Pharmaceutics: the Design and Manufacture of Medicines, third edition, Churchill Livingstone Elsevier, (2011), page 162-165; 443-449, ISBN 9780443101083 | - |
| OPPOSITION | - D16 - Opposition division decision EP2654736 | - |
| OPPOSITION | - D19 - Patentee ’ s reply to the notices of opposition dated 30 August 2021 (EP2654736 proceedings) | - |
| OPPOSITION | - D28 - 1H-NMR von DMSO in CDCl3(8= 2,621 ppm) | - |
| OPPOSITION | - D40 - GSK1120212 Technical Evidence Candidate Selection report, sections 4 and 6 | - |
| OPPOSITION | - D42 - Clinical Overview for Trametinib Monotherapy, pages 1 and 14 | - |
| OPPOSITION | - EDWARD RUDNIC, JOSEPH B SCHWARTZ, "ORAL SOLID DOSAGE FORMS", EDWARD RUDNIC, JOSEPH B SCHWARTZ, ALFONSO R GENNARO, REMINGTON'S PHARMACEUTICAL SCIENCES ED.18, US , MACK PUBLISHING CO. , (19900101), pages I - 1633-1665, ISBN 0-912734-04-3, XP003035751 | - |
| OPPOSITION | - G. Buckton, "8 Solid-state properties", G. Buckton, Michael E. Aulton, Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, Churchill Livingstone Elsevier, (20070101), pages 110 - 120, ISBN 978-0-443-10108-3, XP009561910 | - |
| OPPOSITION | - Göran Alderborn, "Chapter 31: Tablets and compaction", Göran Alderborn, MICHAEL E. AULTON, Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, Churchill Livingstone Elsevier, (20110101), pages 441 - 482, ISBN 978-0-443-10108-3, XP009558969 | - |
| OPPOSITION | - "Hypromellose", Rowe R C, SHESKEY P J, OWEN S C, Handbook of pharmaceutical excipients. Fifth edition REG:177/07, London , Pharmaceutical Press , (20060101), pages 346 - 349, 0318350, ISBN 978-0-85369-618-6, XP055228679 | - |
| OPPOSITION | - Iain L.O. Buxton, "Chapter 1: Pharmacokinetics and Pharmacodynamics - the dynamics of drug absorption, distribution, action and elimination", Iain L.O. Buxton, BRUNTON L.L.; LAZO J.S.; PARKER K.L. (EDS.), GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS., NEW YORK, NY : MCGRAW-HILL.; US , (20060101), pages 1 - 39, 034423, ISBN 978-0-07-142280-2, XP055406047 | - |
| OPPOSITION | - JAMES WELLS, "PHARMACEUTICAL PREFORMULATION: THE PHYSICOCHEMICAL PROPERTIES OF DRUG SUBSTANCES.", JAMES WELLS, AULTON M.E. (ED.).2, PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN ED. 2, UK, CHURCHILL LIVIGSTONE , (20020101), pages I - 113-138, 027702, ISBN 978-0-443-05517-1, XP003035880 | - |
| OPPOSITION | - Marlene Modi, "Dose-Finding Studies in Phase 1and Estimation of Maximally ToleratedDose", Marlene Modi, Naitee Ting, Dose Finding in Drug Development, Springer, (20060101), pages 30 - 48, ISBN 978-0-387-29074-4, XP009559022 | - |
| OPPOSITION | - M. Ashford, "21 Bioavailability - physicochemical and dosage form factors", M. Ashford, MICHAEL E. AULTON, Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, Churchill Livingstone Elsevier, (20070101), pages 286 - 303, ISBN 978-0-443-10108-3, XP009561908 | - |
| OPPOSITION | - M. Ashford, "22 Assessment of biopharmaceutical properties", M. Ashford, MICHAEL E. AULTON, Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, Churchill Livingstone Elsevier, (20070101), pages 304 - 323, ISBN 978-0-443-10108-3, XP009561909 | - |
| OPPOSITION | - Messersmith Wells A, Hidalgo Manuel, Carducci Michael, Eckhardt S Gail, " Novel Targets in Solid Tumors: MEK inhibitors", Clin Adv Hematol Oncol., (20061201), vol. 4, no. 11, pages 831 - 836, XP093281965 | - |
| OPPOSITION | - NA Armstrong, "Sucrose", NA Armstrong, Rowe Raymond C., Handbook of Pharmaceutical Excipients, London , Pharmaceutical Press , (20050817), pages 744 - 747, ISBN 0 85369 618 7, XP009558954 | - |
| OPPOSITION | - Nicholas H. G. Holford. Leslie Z. Benet, "Pharmacokinetics and Pharmacodynamics: Dose Selection and the Time Course of Drug Action", Nicholas H. G. Holford. Leslie Z. Benet, Bertram G. Katzung, Basic & Clinical Pharmacology, 7th Edition, Lange Medical Books / McGraw-Hill, (19980101), pages 34 - 49, ISBN 0-8385-0565-1, XP009561965 | - |
| OPPOSITION | - Raymond C. Rowe Et Al, "Povidone", Raymond C. Rowe Et Al, ROWE R.C., SHESKEY P.J., OWEN S.C.(EDS.), Handbook of Pharmaceutical Excipients, London [u.a.] , Pharmaceutical Press [u.a.] , (20000101), pages 611 - 616, 031835, ISBN 978-1-58212-058-4, XP055396598 | - |
| OPPOSITION | - Raymond C. Rowe, Paul J. Sheskey, Sian C. Owen, "Talc", Handbook of Pharmaceutical Excipients. 5th ed., PhP , (20060101), pages 767 - 769, XP055818594 | - |
| OPPOSITION | - RJ Harwood, "Hydroxyethyl Cellulose", RJ Harwood, Rowe R C, SHESKEY P J, OWEN S C, Handbook of pharmaceutical excipients. Fifth edition, London , Pharmaceutical Press , (20050817), pages 330 - 333, ISBN 0853696187, XP009558937 | - |
| OPPOSITION | - RJ HARWOOD, "HYDROXYPROPYL CELLULOSE", RJ HARWOOD, Royal Pharmaceutical Society of Great Britain, Handbook of Pharmaceutical Excipients, UK/USA , Pharmaceutical Press; The American Pharmacists Association , (20060101), pages 336 - 340, ISBN 0-85369-618-7, XP002765577 | - |
| OPPOSITION | - Ronald W. Miller, "6 Roller Compaction Technology", Ronald W. Miller, Dilip M. Parikh, Handbook of Pharmaceutical Granulation Technology, Taylor & Francis Group, LLC , (20050101), pages 159 - 190, ISBN 0-8247-2647-2, XP009558936 | - |
| OPPOSITION | - Rowe Raymond C., Paul J. Sheskey, Sian C. Owen., "Ethylcellulose", Handbook of pharmaceutical excipients.-5th ed., (20060101), pages 278 - 282, XP055893625 | - |
| OPPOSITION | - ROWE RAYMOND C; SHESKEY PAUL J; OWEN SIAN C, "Handbook of pharmaceutical excipients, Mannitol", ROWE RAYMOND C; SHESKEY PAUL J; OWEN SIAN C, ROWE R.C., SHESKEY P.J., OWEN S.C.(EDS.), Handbook of Pharmaceutical Excipients, London [u.a.] , Pharmaceutical Press [u.a.] , (20060101), vol. 5TH EDITION, pages 449 - 453, 031835, ISBN 978-1-58212-058-4, XP002537758 | - |
| OPPOSITION | - ROWE R C ET AL, "CELLULOSE, MICROCRYSTALLINE", ROWE R C ET AL, ROWE R.C., SHESKEY P.J., OWEN S.C.(EDS.), Handbook of Pharmaceutical Excipients, London [u.a.] , Pharmaceutical Press [u.a.] , (20060101), pages 132 - 135, 031835, ISBN 978-1-58212-058-4, XP002520963 | - |
| OPPOSITION | - Rowe R. C., Et Al, "Starch", Handbook of pharmaceutical excipients. 5 th ed., PhP , (20060101), pages 725 - 730, XP055480758 | - |
| OPPOSITION | - Serajuddin, A.T.M., "Salt formation to improve drug solubility", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (20070824), vol. 59, no. 7, doi:10.1016/j.addr.2007.05.010, ISSN 0169-409X, pages 603 - 616, XP022211982 | |
| OPPOSITION | - Jessie Villanueva, Adina Vultur, John T. Lee, Rajasekharan Somasundaram, Mizuho Fukunaga-Kalabis, Angela K. Cipolla, Bradley Wubbenhorst, Xiaowei Xu, Phyllis A. Gimotty, Damien Kee, Ademi E. Santiago-Walker, Richard Letrero, Kurt D'andrea, Anitha Pushparajan, James E. Hayden, Kimberly Dahlman Brown, Sylvie Laquerre, Grant A. Mcarthur, Jeffrey A. Sosman, Katherine L. Nathanson, Meenhard Herlyn, "Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K", Cancer cell, Cell Press, (20101201), vol. 18, no. 6, doi:10.1016/j.ccr.2010.11.023, ISSN 15356108, pages 683 - 695, XP055057543 | |
| OPPOSITION | - Kun E.; Tsang Y.T.M.; Ng C.W.; Gershenson D.M.; Wong K.K., "MEK inhibitor resistance mechanisms and recent developments in combination trials", Cancer Treatment Reviews, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20201216), vol. 92, doi:10.1016/j.ctrv.2020.102137, ISSN 0305-7372, XP086470131 | |
| OPPOSITION | - Planchard David; Besse Benjamin; Groen Harry J M; Souquet Pierre-Jean; Quoix Elisabeth; Baik Christina S; Barlesi Fabrice; Kim Tae Min; Mazieres Julien; Novello Silvia; Rigas James R; Upalawanna Allison; D'Amelio Anthony M; Zhang Pingkuan; Mookerjee Bijoyesh; Johnson Bruce E, "Dabrafenib plus trametinib in patients with previously treatedBRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20160606), vol. 17, no. 7, doi:10.1016/S1470-2045(16)30146-2, pages 984 - 993, XP029625484 | |
| OPPOSITION | - Hiroyuki Abe, Shinichi Kikuchi, Kazuhide Hayakawa, Tetsuya Iida, Noboru Nagahashi, Katsuya Maeda, Johei Sakamoto, Noriaki Matsumoto, Tomoya Miura, Koji Matsumura, Noriyoshi Seki, Takashi Inaba, Hisashi Kawasaki, Takayuki Yamaguchi, Reina Kakefuda, Toyomichi Nanayama, Hironori Kurachi, Yoshikazu Hori, Takayuki Yoshida, Junya Kakegawa, Yoshihiro Watanabe, Aidan G. Gilmartin, Mark C. Richter, Katherine G. Moss, Sylvie G. Laquerre, "Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)", ACS Medicinal Chemistry Letters, American Chemical Society, (20110414), vol. 2, no. 4, doi:10.1021/ml200004g, ISSN 19485875, pages 320 - 324, XP055209291 | |
| OPPOSITION | - K S M Smalley, K T Flaherty, "Integrating BRAF/MEK inhibitors into combination therapy for melanoma", British Journal of Cancer, Harcourt Publishers, (20090210), vol. 100, no. 3, doi:10.1038/sj.bjc.6604891, ISSN 00070920, pages 431 - 435, XP055123646 | |
| OPPOSITION | - C. Le Tourneau, J. J. Lee, L. L. Siu, "Dose Escalation Methods in Phase I Cancer Clinical Trials", JNCI Journal of the National Cancer Institute, (20090520), vol. 101, no. 10, doi:10.1093/jnci/djp079, ISSN 00278874, pages 708 - 720, XP055071486 | |
| OPPOSITION | - J. Greshock, K. E. Bachman, Y. Y. Degenhardt, J. Jing, Y. H. Wen, S. Eastman, E. Mcneil, C. Moy, R. Wegrzyn, K. Auger, M. A. Hardwicke, R. Wooster, "Molecular Target Class Is Predictive of In vitro Response Profile", Cancer research, American Association for Cancer Research, (20100501), vol. 70, no. 9, doi:10.1158/0008-5472.CAN-09-3788, ISSN 00085472, pages 3677 - 3686, XP055104085 | |
| OPPOSITION | - Anonymous Patricia M., Krishnamurthi Smitha S., Rinehart John J., Nabell Lisle M., Malburg Lisa, Chapman Paul B., Deprimo Samuel E., Bentivegna Steven, Wilner Keith D., Tan Weiwei, Ricart Alejandro D., "Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers | Clinical Cancer Research | American Association for Cancer Research", Cancer Research, Association for Cancer Research, US, US, (20100315), vol. 16, no. 6, doi:10.1158/1078-0432.CCR-09-1883, ISSN 1078-0432, pages 1924 - 1937, XP093214480 | |
| OPPOSITION | - A. G. Gilmartin, M. R. Bleam, A. Groy, K. G. Moss, E. A. Minthorn, S. G. Kulkarni, C. M. Rominger, S. Erskine, K. E. Fisher, J. Yang, F. Zappacosta, R. Annan, D. Sutton, S. G. Laquerre, "GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition", Clinical Cancer Research, Association for Cancer Research, US, US, (20110301), vol. 17, no. 5, doi:10.1158/1078-0432.CCR-10-2200, ISSN 1078-0432, pages 989 - 1000, XP055275253 | |
| OPPOSITION | - Daouti Sherif, Higgins Brian, Kolinsky Kenneth, Packman Kathryn, Wang Huisheng, Rizzo Christine, Moliterni John, Huby Nicholas, Fotouhi Nader, Liu Mei, Goelzer Petra, Sandhu Harpreet K., Li Jia Kui, Railkar Aruna, Heimbrook David, Niu Huifeng, "Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20100101), vol. 9, no. 1, doi:10.1158/1535-7163.MCT-09-0601, ISSN 1535-7163, pages 134 - 144, XP093281969 | |
| OPPOSITION | - Frémin Christophe, Meloche Sylvain, "From basic research to clinical development of MEK1/2 inhibitors for cancer therapy", Journal of Hematology & Oncology, BioMed Central Ltd, London UK, London UK , (20101201), vol. 3, no. 1, doi:10.1186/1756-8722-3-8, ISSN 1756-8722, XP093237298 | |
| OPPOSITION | - Patricia M. LoRusso, Alex A. Adjei, Mary Varterasian, Shirish Gadgeel, Joel Reid, David Y. Mitchell, Lorelei Hanson, Pamela DeLuca, Laura Bruzek, Jill Piens, Peggy Asbury, Keri Van Becelaere, Roman Herrera, Judith Sebolt-Leopold, and Mark B. Meyer, "Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies", Journal of Clinical Oncology, (20050810), vol. 23, no. 23, doi:10.1200/JCO.2005.14.415, pages 5281 - 593, XP055540372 | |
| OPPOSITION | - Adjei Alex A., Cohen Roger B., Franklin Wilbur, Morris Clive, Wilson David, Molina Julian R., Hanson Lorelei J., Gore Lia, Chow Laura, Leong Stephen, Maloney Lara, Gordon Gilad, Simmons Heidi, Marlow Allison, Litwiler Kevin, Brown Suzy, Poch Gregory, Kane Katie, Haney Jerry, Eckhardt S. Gail, "Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers", Journal of Clinical Oncology, American Society of Clinical Oncology, (20080501), vol. 26, no. 13, doi:10.1200/JCO.2007.14.4956, ISSN 0732-183X, pages 2139 - 2146, XP093281968 | |
| OPPOSITION | - Thompson D. S., Flaherty K., Messersmith W., Harlacker K., Nallapareddy S., Vincent C., Demarini D. J., Cox D. S., O'neill V. J., Burris H. A., "A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma", Journal of Clinical Oncology, Grune & Stratton, (20090520), vol. 27, no. 15_suppl, doi:10.1200/jco.2009.27.15_suppl.e14584, ISSN 0732-183X, pages e14584 - e14584, XP093237287 | |
| OPPOSITION | - Infante J. R., Fecher L. A., Nallapareddy S., Gordon M. S., Flaherty K. T., Cox D. S., Demarini D. J., Morris S. R., Burris H. A., Messersmith W. A., "Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.", Journal of Clinical Oncology, Grune & Stratton, (20100520), vol. 28, no. 15_suppl, doi:10.1200/jco.2010.28.15_suppl.2503, ISSN 0732-183X, pages 2503 - 2503, XP093237289 | |
| OPPOSITION | - Messersmith W. A., Falchook G. S., Fecher L. A., Gordon M. S., Vogelzang N. J., Demarini D. J., Peddareddigari V. G., Xu Y., Bendell J. C., Infante J. R., "Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer.", Journal of Clinical Oncology, Grune & Stratton, (20110201), vol. 29, no. 4_suppl, doi:10.1200/jco.2011.29.4_suppl.246, ISSN 0732-183X, pages 246 - 246, XP093237324 | |
| OPPOSITION | - Roberta Censi, Piera Di Martino, "Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs", Molecules, vol. 20, no. 10, doi:10.3390/molecules201018759, pages 18759 - 18776, XP055425363 | |
